Mglur5 (Grm5) Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Neurons expressing metabotropic glutamate receptor 5 (GRM5, also known as mGluR5) represent a critical component of the glutamatergic signaling system in the brain. GRM5 is a Group I metabotropic glutamate receptor that couples to Gq proteins and plays essential roles in synaptic plasticity, learning and memory, and neurological disease pathogenesis. This receptor is a major therapeutic target for neurological and psychiatric disorders.
GRM5-expressing neurons are widely distributed:
- Hippocampus: High expression in CA1-CA3 pyramidal neurons, dentate gyrus granule cells
- Cortex: Layers II-III and V, pyramidal neurons and interneurons
- Striatum: Medium spiny neurons, GABAergic projection neurons
- Basal ganglia: Substantia nigra pars reticulata, globus pallidus
- Thalamus: Intralaminar nuclei, relay nuclei
- Cerebellum: Purkinje cells, deep nuclei
- Brainstem: Various nuclei involved in motor control
GRM5 is an 118-kDa class C GPCR:
- Belongs to Group I mGluRs (mGluR1, mGluR5)
- Large extracellular venus fly trap domain for glutamate binding
- Distinct splice variants (mGluR5a, mGluR5b)
- Gq protein coupling activates PLCβ
- Generates IP3 and DAG second messengers
- Releases intracellular calcium from stores
- Forms homomers and heteromers with other mGluRs
- Interacts with Homer scaffolding proteins
- Regulates NMDA receptor function
- Modulates AMPA receptor trafficking
- Controls presynaptic release probability
- Generates slow excitatory postsynaptic potentials
- Critical for LTPmechanisms/long-term-potentiation) and LTD induction
- Regulates dendritic spine morphology
- Controls actin cytoskeleton remodeling
- Mediates learning and memory
- Mobilizes intracellular calcium stores
- Activates calcium-dependent enzymes
- Regulates gene transcription
- Triggers structural plasticity
- Neuronal development and migration
- Axon guidance
- Neuroprotection (under certain conditions)
- Pain perception (peripheral and central)
- GRM5 dysfunction contributes to synaptic deficits
- Amyloid-beta interacts with mGluR5
- Altered expression in AD brains
- Target for cognitive enhancement
- GRM5 in basal ganglia motor circuits
- Modulates dopaminergic signaling
- Contributes to levodopa-induced dyskinesias
- Target for motor complications
- GRM5 hyperactivation contributes to excitotoxicity
- Mutant huntingtin alters mGluR5 signaling
- Target for neuroprotection
- Modulates striatal dysfunction
- GRM5 is a key therapeutic target
- Excessive mGluR5 signaling
- Negative allosteric modulators in clinical trials
- Improves synaptic function
- GRM5 antagonists show antidepressant effects
- Rapid-acting mechanisms
- Novel treatment target
- Modulates stress circuits
- Anxiogenic effects of GRM5 activation
- Anxiolytic effects of antagonists
- Target for anxiety disorders
- mGluR5 in pain transmission
- Peripheral and central mechanisms
- Target for analgesics
- Pro-convulsant effects of GRM5 activation
- Anticonvulsant potential of antagonists
- Target for anti-epileptic drugs
GRM5 is a clinically validated drug target:
- Mavoglurant (AFQ056): Clinical trials for Fragile X syndrome
- Basimglurant (RO4917523): Depression and anxiety trials
- Dipraglurant: Levodopa-induced dyskinesias
- CDPPB: Cognitive enhancement
- ADX47273: Investigational for schizophrenia
- Fragile X syndrome: mGluR5 NAMs improve symptoms
- Depression: Fast-acting antidepressants
- Levodopa-induced dyskinesias: Reduce dyskinesias
- Anxiety disorders: Anxiolytic potential
- 11CABP688: PET ligand for mGluR5
- Measures receptor availability
- Research and clinical applications
GRM5 serves as a biomarker:
- Genetic markers: GRM5 polymorphisms in disease
- Imaging: PET ligands for receptor density
- Expression: Postmortem brain studies
- Functional: Treatment response prediction
The study of Mglur5 (Grm5) Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.